Francis Medical Showcases Vanquish Water Vapor Ablation System at Major Urology Congress

According to a recent LinkedIn post from Francis Medical, the company is participating in the 41st Annual European Association of Urology Congress (EAU26) in London, described as a major European urology gathering. The post notes that CEO Mike Kujak and Director of Global Commercial Marketing James Wright are on site to engage with urologists, healthcare practitioners, and urology networks globally.

The company’s LinkedIn post highlights its 510(k) cleared Vanquish® Water Vapor Ablation System, characterized as a minimally invasive, transurethral technology for targeted prostate tissue ablation using sterile water vapor thermal energy. The emphasis on FDA clearance and Rx-only status may signal that the product is at a commercialization-ready stage in the U.S., which could support near- to medium-term revenue growth if clinical uptake and reimbursement environments are favorable.

From an investment perspective, the presence at EAU26 suggests a focus on international clinician outreach and potential market expansion beyond the U.S., particularly in Europe’s urology community. If Francis Medical converts this exposure into clinical adoption, partnerships, or distribution agreements, it could strengthen its competitive positioning in the prostate health and medtech ablation segment, though the post does not provide specific commercial metrics or timelines.